Mitsubishi Tanabe Pharma America, Inc., announced the presentation of five abstracts in amyotrophic lateral sclerosis (ALS) at the XXVI World Congress of Neurology (WCN), being held virtually and in-person in Montreal, Quebec, October 15-19.
“We look forward to joining the scientific community at this year’s meeting where we will highlight our latest ALS research, including findings from our real-world and clinical studies of RADICAVA ORS® (edaravone) and RADICAVA® (edaravone),” said Gustavo A. Suarez Zambrano, M.D., Vice President of Medical Affairs at MTPA. “These presentations reflect the importance of combining insights from clinical and real-world settings to better understand the potential of our current treatment options and their impact on ALS.”
MTPA’s posters will be viewable in the Virtual Platform and onsite throughout the conference. Presentations include:
Also Read : Cryoport Inks New Multi-Year Supply Chain Solutions Agreement with Monash IVF
Real-World Data
A real-world analysis describing patient demographics, clinical characteristics and treatment outcomes in people with ALS being treated with intravenous (IV) RADICAVA, based on data collected from a U.S. provider of home and alternate-site infusions, will be presented, in addition to findings from an analysis of time to progression milestones in people treated with RADICAVA utilizing de-identified data from Optum’s Clinformatics® Data Mart (CDM) database.
- Treatment Outcomes for Patients with Amyotrophic Lateral Sclerosis Receiving Intravenous Edaravone from a Home and Alternative-Site Infusion Provider (Agessandro Abrahão, M.D., M.Sc., Sunnybrook Health Sciences Centre)
Oral Presentation (Free Paper: Motor Neurone Disease): 3:00 p.m. – 3:12 p.m. EDT, October 16 - Longer Milestone-Free Time in IV Edaravone–Treated vs Non–IV Edaravone-Treated Patients with Amyotrophic Lateral Sclerosis: an Administrative Claims Analysis (Malgorzata Ciepielewska, M.S.; MTPA)
Poster #175
SOURCE : PRNewswire